Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
PROCEPT BioRobotics (PRCT)
NASDAQ:PRCT
PROCEPT BioRobotics (PRCT) Stock Price & Analysis
140 Followers
PRCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$24.83 - $77.00
Previous Close$61.87
Volume387.51K
Average Volume (3M)623.01K
Market Cap
$3.18B
Enterprise Value$3.00B
Total Cash (Recent Filing)$257.20M
Total Debt (Recent Filing)$79.20M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Aug 01, 2024EPS Estimate
-$0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.12
Shares Outstanding51,424,151
10 Day Avg. Volume583,164
30 Day Avg. Volume623,010
Standard Deviation0.17
R-Squared0.11
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)11.02
Price to Sales (P/S)22.63
Price to Cash Flow (P/CF)-31.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue22.05
Enterprise Value/Gross Profit42.28
Enterprise Value/Ebitda-38.69
Forecast
1Y Price Target
$70.25Price Target Upside11.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
PROCEPT BioRobotics News
Bulls Say, Bears Say
Bulls Say
Clinical SuccessThe PRCT-001 study, evaluating the safety and efficacy of Aquablation therapy for patients with BPH and localized prostate cancer, demonstrated highly positive results.
Market PotentialThe clinical value proposition of Aquablation therapy in BPH was showcased along with the potential for the therapy to fill an unmet clinical need in low and intermediate risk prostate cancer.
Revenue GrowthPRCT reported another quarter of strong commercial execution, delivering 1Q24 revenue 7% ahead of consensus.
Bears Say
Growth EffortsWorry that the placement of an AquaBeam into an ASC is indicative of a small but burgeoning effort to seek growth beyond the hospital setting.
Market SaturationConcern that PRCT will saturate its existing high volume hospital market forcing a shift in capital sales to the ASC and physician office setting.
Payment DiscrepanciesThere are cases where the Cat I payment turned out lower than the prior average Cat III payment.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PRCT FAQ
What was PROCEPT BioRobotics’s price range in the past 12 months?
PROCEPT BioRobotics lowest stock price was $24.83 and its highest was $77.00 in the past 12 months.
What is PROCEPT BioRobotics’s market cap?
Currently, no data Available
When is PROCEPT BioRobotics’s upcoming earnings report date?
PROCEPT BioRobotics’s upcoming earnings report date is Aug 01, 2024 which is in 29 days.
How were PROCEPT BioRobotics’s earnings last quarter?
PROCEPT BioRobotics released its earnings results on May 01, 2024. The company reported -$0.51 earnings per share for the quarter, beating the consensus estimate of -$0.555 by $0.045.
Is PROCEPT BioRobotics overvalued?
According to Wall Street analysts PROCEPT BioRobotics’s price is currently Undervalued.
Does PROCEPT BioRobotics pay dividends?
PROCEPT BioRobotics does not currently pay dividends.
What is PROCEPT BioRobotics’s EPS estimate?
PROCEPT BioRobotics’s EPS estimate is -$0.52.
How many shares outstanding does PROCEPT BioRobotics have?
PROCEPT BioRobotics has 51,424,152 shares outstanding.
What happened to PROCEPT BioRobotics’s price movement after its last earnings report?
PROCEPT BioRobotics reported an EPS of -$0.51 in its last earnings report, beating expectations of -$0.555. Following the earnings report the stock price went up 14.402%.
Which hedge fund is a major shareholder of PROCEPT BioRobotics?
Among the largest hedge funds holding PROCEPT BioRobotics’s share is Driehaus Capital Management LLC. It holds PROCEPT BioRobotics’s shares valued at 14M.
---
PROCEPT BioRobotics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$70.25 (11.23% Upside)
$70.25 (11.23% Upside)
Blogger Sentiment
Bullish
PRCT Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 117.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
75.02%
12-Months-Change
Fundamentals
Return on Equity
-47.29%
Trailing 12-Months
Asset Growth
34.61%
Trailing 12-Months
Company Description
PROCEPT BioRobotics
PROCEPT BioRobotics Corp is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology.
---
PRCT Company Deck
---
PRCT Earnings Call
Q1 2024
0:00 / 0:00
---
PRCT Stock 12 Month Forecast
Average Price Target
$70.25
▲(11.23% Upside)
Technical Analysis
Best Analysts Covering PRCT
1 Year
1 Year Success Rate
13/15 ratings generated profit
1 Year Average Return
+44.39%
assigned a buy rating 2 months ago
Copying Richard Newitter's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +44.39% per trade.
---